Cannabinoid-Derived Pharmaceuticals Industry Review Summit

Jan 19, 2021, 9:00 AM
Dec 21, 2020, 5:00 PM
by Hanson Wade
Hilton London Kensington

About Cannabinoid-Derived Pharmaceuticals Industry Review Summit

Welcome to Cannabinoid Derived Pharmaceuticals Summit Europe

The inaugural Cannabinoid-Derived Pharmaceuticals Industry Review 2021 seeks to unite drug developers and researchers working on the complex and challenging development of both plant-based and synthetic modulators of the endocannabinoid system and ultimately speed the development of better pharmaceutical & otc-drugs products. 


Set your organisation up for success in the coming 12 months by learning from a comprehensive array of key opinion leaders in the field. Helping you create a robust plan that will help you advance your compounds from preclinical assessment and through the clinic, set up a commercial strategy to scale up your operations efficiently and be prepared for regulatory scrutiny in this constantly evolving regulatory environment.


This focused conference will put you in front of the research teams exploring the future of therapeutic cannabinoids in a host of disease areas for patients with unmet clinical needs. 


With 20+ hours of content, an interactive workshop on finance and funding and 5 hours+ of networking with your fellow drug developers, this is the only European conference solely focused on the application of cannabinoids for pharmaceutical use in a range of disease indications. 


Cannabinoid derived pharmaceuticals have faced many challenges in their development. Cannabis prohibition being the original and biggest obstruction to progress. Now the industry has started facing new, more acute challenges like finding suitable patient populations and designing robust trials, working with regulators around the world with varying attitudes towards cannabis, selecting the most pharmacologically appropriate synthetic or phytocannabinoid possible just to name a few. Along with the challenges COVID-19 has created over the past months many of these other challenges have been facing the industry for years.   

Introducing the first Cannabinoid Derived Pharmaceuticals Industry Review Summit, taking place virtually 19th – 21st January.Attending online will give you access to the same opportunities as a physical attendee through our purpose-built online conference platform. 


With 20+ hours of content, an interactive pre-conference funding and finance workshop and 5 hours+ of networking with your fellow drug developers, this is the only conference solely focused on the application of cannabinoids for pharmaceutical use in a range of disease indications. 


Reasons to Attend

Join us as we unite experts from across large pharma, innovative biotechs, academia and solution providers to overcome all the end to end challenges which are holding back therapeutic and commercial success in cannabinoid-based drug development. 


Simon Benita
Professor & Chairman Hebrew University of Jerusalem, BioNanoSim Ltd
Chief of R&D CannnRx
Clifton Flack
CEO & Co-Founder CiiTECH
R&D Coordinator Entourage Phytolab
Rob Dhoble
Managing Director Havas ECS
View More (17)
Senior Clinical Lecturer Imperial College London
Director of Drug Development InMed Pharmaceuticals
VP Chemistry Manufacturing and Control InMed Pharmaceuticals
CSO International Research Center on Cannabis and Health
Nick Pateras
Managing Director, Europe Materia Global
CEO Orpheus Medica
CEO Pascal Biosciences
President & COO Phytecs
Tamás Bíró
Director of Applied Research Phytecs
CSO Receptor Life Sciences
CEO and Co-Founder RespireRx Pharmaceuticals
Cynthia El Hage
Director of Research & Innovation Santé Cannabis
Vice-President Clinical Programs/ Medical Affairs Tetra Bio-Pharma
Associate Professor of Biopharmaceutics University of Nottingham
Professor of Neurology University of Nottingham
Professor & Chair of Biochemistry and Molecular Biology University of Rome
Robin Emerson
Medical Cannabis Campaigner


Havas ECS
Entourage Phytolab